Sachetta LLC Sells 4,578 Shares of Merck & Co., Inc. $MRK

Sachetta LLC decreased its position in Merck & Co., Inc. (NYSE:MRK) by 69.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,972 shares of the company’s stock after selling 4,578 shares during the period. Sachetta LLC’s holdings in Merck & Co., Inc. were worth $208,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Barnes Dennig Private Wealth Management LLC boosted its holdings in Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after acquiring an additional 266 shares in the last quarter. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. in the third quarter valued at $31,000. Wealth Watch Advisors INC bought a new stake in Merck & Co., Inc. in the third quarter valued at $34,000. Dunhill Financial LLC boosted its holdings in Merck & Co., Inc. by 83.0% in the third quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock valued at $35,000 after acquiring an additional 190 shares in the last quarter. Finally, Silicon Valley Capital Partners boosted its holdings in Merck & Co., Inc. by 160.5% in the third quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock valued at $35,000 after acquiring an additional 260 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — Merck posted revenue and adjusted EPS above Street forecasts with Keytruda and Winrevair driving growth; the beats and upbeat commentary lifted investor sentiment. Merck tops Q1 estimates
• Positive Sentiment: Regulatory approvals & pipeline progress expand addressable markets — Merck won FDA approval for a new 2?drug HIV regimen (IDVYNSO) and EC approval for ENFLONSIA for RSV prevention; the company also dosed the first patient in Phase 3 enpatoran lupus trials, adding long?term growth optionality. Merck expands beyond oncology
• Neutral Sentiment: Analyst action mixed — Wells Fargo trimmed its price target to $145 but kept an Overweight rating, signaling continued confidence despite a modestly lower PT. Wells Fargo lowers PT
• Neutral Sentiment: FY?2026 guidance and outlook — Merck provided EPS guidance of $5.04–$5.16 and a narrowed sales view ($65.8B–$67.0B). Guidance is close to consensus but tighter ranges mean less revenue upside visibility near term. Merck Q1 financial results
• Neutral Sentiment: Sector context — Biotech peers are mixed (Moderna saw vaccine revenue rebound but its stock fell; Organon missed), so some moves reflect broader healthcare rotation rather than Merck?specific news. Moderna Covid vaccine drives growth
• Negative Sentiment: Acquisition-related charge produced a GAAP loss — A Cidara-related charge drove a quarterly GAAP loss, which clouds headline profitability despite the operational beat. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Longer-term growth risks flagged — Coverage noted potential future pressure from lost sales on some products (e.g., competitive threats to Keytruda, HPV and diabetes medicines) and Merck said it is working on mitigations. That risk keeps some investors cautious. Merck stock falls after earnings

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $112.30 on Friday. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The stock has a market cap of $277.36 billion, a PE ratio of 31.63, a price-to-earnings-growth ratio of 2.27 and a beta of 0.19. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The company’s fifty day moving average price is $117.69 and its 200-day moving average price is $107.54.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 26.84%. The firm had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the previous year, the business posted $2.22 EPS. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 4.9 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Cantor Fitzgerald lifted their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Monday, March 30th. Wells Fargo & Company cut their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday. JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a report on Monday, April 6th. Finally, Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $128.18.

Insider Activity

In other news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the sale, the insider owned 21,197 shares in the company, valued at approximately $2,583,278.39. The trade was a 41.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.17% of the stock is currently owned by corporate insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.